Benign Prostatic Hyperplasia - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 133 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Benign Prostatic Hyperplasia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Benign Prostatic Hyperplasia - Pipeline Review, H1 2015', provides an overview of the Benign Prostatic Hyperplasia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Benign Prostatic Hyperplasia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Benign Prostatic Hyperplasia Overview 10
Therapeutics Development 11
Pipeline Products for Benign Prostatic Hyperplasia - Overview 11
Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis 12
Benign Prostatic Hyperplasia - Therapeutics under Development by Companies 13
Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes 15
Benign Prostatic Hyperplasia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Benign Prostatic Hyperplasia - Products under Development by Companies 20
Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes 23
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development 24
AbbVie Inc. 24
Addex Therapeutics Ltd 25
AmVac AG 26
AndroScience Corporation 27
Aphios Corporation 28
Ausio Pharmaceuticals, LLC 29
Biolab Sanus Farmaceutica Ltda. 30
Chong Kun Dang Pharmaceutical Corp. 31
Corium International, Inc. 32
Curadis GmbH 33
Euroscreen S.A. 34
Hanmi Pharmaceuticals, Co. Ltd. 35
IntelGenx Corp. 36
Jeil Pharmaceutical Co., Ltd. 37
KAEL-GemVax Co., Ltd. 38
Kaken Pharmaceutical Co., Ltd. 39
Meiji Seika Pharma Co., Ltd. 40
Mezzion Pharma Co. Ltd. 41
Neurocentrx Pharma Ltd. 42
Nymox Pharmaceutical Corporation 43
Ono Pharmaceutical Co., Ltd. 44
Quest PharmaTech Inc. 45
SK Chemicals Co., Ltd. 46
SOM Innovation Biotech SL 47
Sophiris Bio, Inc. 48
Yungjin Pharm Ind. Co., Ltd. 49
Benign Prostatic Hyperplasia - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 54
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
(tamsulosin hydrochloride + dutasteride) - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ADX-68692 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
AMV-110 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ASC-JM.X2 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AUS-131 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BL-214 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CKD-902 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CR-1493 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Drugs for Burning Sensation - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ESN-364 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
HCP-1303 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
HIP-1402 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
INT-0031 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
JLP-1207 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
L-1AD3 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
MCS-2 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
NCE-403 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NX-1207 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ONO-8430506 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
S-40542 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SL-052 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
SOM-2391 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
SOM-2393 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Sperol - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
talaporfin sodium - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
tamsulosin hydrochloride - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
tamsulosin hydrochloride CR - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
tertomotide - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
topsalysin - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
udenafil - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
YBH-1603 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
YOB-1604 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Benign Prostatic Hyperplasia - Recent Pipeline Updates 103
Benign Prostatic Hyperplasia - Dormant Projects 119
Benign Prostatic Hyperplasia - Discontinued Products 123
Benign Prostatic Hyperplasia - Product Development Milestones 125
Featured News & Press Releases 125
Apr 01, 2015: Nymox Announces Phase 3 BPH Studies 125
Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 125
Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints 126
Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 126
Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH 127
Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study 127
Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 128
Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug 129
May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH 129
Nov 11, 2013: Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH 130
Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 132
Contact Us 132
Disclaimer 133

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2015 11
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Comparative Analysis by Unknown Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Products under Development by Companies, H1 2015 (Contd..2) 22
Products under Investigation by Universities/Institutes, H1 2015 23
Benign Prostatic Hyperplasia - Pipeline by AbbVie Inc., H1 2015 24
Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H1 2015 25
Benign Prostatic Hyperplasia - Pipeline by AmVac AG, H1 2015 26
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H1 2015 27
Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H1 2015 28
Benign Prostatic Hyperplasia - Pipeline by Ausio Pharmaceuticals, LLC, H1 2015 29
Benign Prostatic Hyperplasia - Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 30
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 31
Benign Prostatic Hyperplasia - Pipeline by Corium International, Inc., H1 2015 32
Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H1 2015 33
Benign Prostatic Hyperplasia - Pipeline by Euroscreen S.A., H1 2015 34
Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 35
Benign Prostatic Hyperplasia - Pipeline by IntelGenx Corp., H1 2015 36
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 37
Benign Prostatic Hyperplasia - Pipeline by KAEL-GemVax Co., Ltd., H1 2015 38
Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015 39
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 40
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 41
Benign Prostatic Hyperplasia - Pipeline by Neurocentrx Pharma Ltd., H1 2015 42
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H1 2015 43
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 44
Benign Prostatic Hyperplasia - Pipeline by Quest PharmaTech Inc., H1 2015 45
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H1 2015 46
Benign Prostatic Hyperplasia - Pipeline by SOM Innovation Biotech SL, H1 2015 47
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H1 2015 48
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 49
Assessment by Monotherapy Products, H1 2015 50
Assessment by Combination Products, H1 2015 51
Number of Products by Stage and Target, H1 2015 53
Number of Products by Stage and Mechanism of Action, H1 2015 55
Number of Products by Stage and Route of Administration, H1 2015 57
Number of Products by Stage and Molecule Type, H1 2015 59
Benign Prostatic Hyperplasia Therapeutics - Recent Pipeline Updates, H1 2015 103
Benign Prostatic Hyperplasia - Dormant Projects, H1 2015 119
Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H1 2015 120
Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H1 2015 121
Benign Prostatic Hyperplasia - Dormant Projects (Contd..3), H1 2015 122
Benign Prostatic Hyperplasia - Discontinued Products, H1 2015 123
Benign Prostatic Hyperplasia - Discontinued Products (Contd..1), H1 2015 124